Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAD | Q92934 | 2/20 | 0.88 |
| ▸ | BCL2 | P10415 | 11/20 | 0.79 |
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.74 |
| ▸ | BCL2L2 | Q92843 | 2/20 | 0.74 |
| ▸ | MDM4 | O15151 | 1/20 | 0.74 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | BID | P55957 | 1/20 | 0.74 |
| ▸ | BAX | Q07812 | 1/20 | 0.74 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.74 |
| ▸ | ASPH | Q12797 | 1/20 | 0.74 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.74 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.74 |
| ▸ | BBC3 | Q9BXH1 | 1/20 | 0.74 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25422286 | 1.00 | BAD (0.88) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL1541222 | 0.94 | BAD (1.00) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL1540844 | 0.90 | BCL2 (0.87) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL2023941 | 0.90 | BCL2 (0.87) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL1541327 | 0.90 | BCL2 (0.86) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL1541323 | 0.90 | BCL2 (0.86) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL1541555 | 0.90 | BCL2 (0.86) | BADBCL2BCL2L1BCL2L2MDM4 | |
| Hydrochloric Acid SCHEMBL25421407 | 0.89 | BAD (0.83) | BADBCL2BCL2L1BCL2L2MDM4 | |
| Hydrochloric Acid SCHEMBL25421393 | 0.89 | BAD (0.83) | BADBCL2BCL2L1BCL2L2MDM4 | |
| SCHEMBL2019324 | 0.89 | BCL2 (1.00) | BADBCL2BCL2L1BCL2L2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | BAD 16/4885BCL2 1/4885BCL2L1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.